Financial Comparison: Upstream Bio (NASDAQ:UPB) and Neuphoria Therapeutics (NASDAQ:NEUP)

Neuphoria Therapeutics (NASDAQ:NEUP) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings for Neuphoria Therapeutics and Upstream Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
Upstream Bio	1	2	4	0	2.43

Neuphoria Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 101.15%. Upstream Bio has a consensus price target of $29.67, indicating a potential upside of 892.20%. Given Upstream Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than Neuphoria Therapeutics.

Insider & Institutional Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Earnings and Valuation

This table compares Neuphoria Therapeutics and Upstream Bio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17 million	16.09	-$13.45 million	($6.22)	-0.56
Upstream Bio	$2.85 million	57.46	-$143.44 million	($2.90)	-1.03

Neuphoria Therapeutics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neuphoria Therapeutics and Upstream Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Summary

Upstream Bio beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.